Table 1.
Ledipasvir/Sofosbuvir for 8 Weeks (N = 27) |
|
---|---|
Male sex, n (%) | 27 (100) |
Median age, y (IQR) | 46 (38–50) |
White, non-Hispanic, n (%) | 11 (41) |
Black, non-Hispanic, n (%) | 5 (19) |
Hispanic or Latino (regardless of race), n (%) | 9 (33) |
Asian or Pacific Islander, n (%) | 2 (7) |
Intravenous drug use, n (%) | |
Current | 1 (4%) |
Previous | 4 (15%) |
Reported history of STI, n (%) | 11 (41) |
IL28B CC favorable genotype, n (%) | 16 (59) |
HCV genotype, n (%) | |
1a | 23 (85) |
1b | 3 (11) |
4 | 1 (4) |
First HCV infection, n (%) | 22 (81) |
Median HCV RNA load, IU/mL (IQR) | 1 490 000 (32 500-3 560 000) |
Median HCV RNA load, log10 IU/mL (IQR) | 6.17 (4.51–6.55) |
HCV RNA load ≥ 6 million IU/mL, n (%) | 6 (22) |
Median time (days) from first laboratory evidence of acute infection (IQR) | 116 (98–156) |
Median CD4, cells/µL (IQR) | 561 (441–698) |
HIV-1 RNA <50 copies/mL, n (%) | 27 (100) |
Median ALT, mg/dL (IQR) | 133 (47–393) |
Median AST, mg/dL (IQR) | 83 (35–224) |
Median total bilirubin, mg/dL (IQR) | 0.60 (0.50–1.20) |
Median creatinine, mg/dL (IQR) | 0.96 (0.88–1.15) |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IL28B, interleukin 28B; IQR, interquartile range; STI, sexually-transmitted infection.